CDKN1A upregulation and cisplatin‑pemetrexed resistance in non‑small cell lung cancer cells
CDKN1A upregulation and cisplatin‑pemetrexed resistance in non‑small cell lung cancer cells
About this item
Full title
Author / Creator
Publisher
Athens: Spandidos Publications
Journal title
Language
English
Formats
Publication information
Publisher
Athens: Spandidos Publications
Subjects
More information
Scope and Contents
Contents
Cisplatin-pemetrexed is a frequently adopted first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) ineligible for biological therapy, notwithstanding its limited efficacy. In the present study, the RAL cell line, an epidermal growth factor receptor (EGFR)-wild-type, p53- and KRAS-mutated model of NSCLC, was used to inve...
Alternative Titles
Full title
CDKN1A upregulation and cisplatin‑pemetrexed resistance in non‑small cell lung cancer cells
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7170038
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7170038
Other Identifiers
ISSN
1019-6439
E-ISSN
1791-2423
DOI
10.3892/ijo.2020.5024
